Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Pioglitazone, a drug used in treatment of type 2 diabetes has been shown to improve insulin
sensitivity in skeletal muscle, liver, and fat cells. Despite the beneficial effects of
pioglitazone to improve insulin sensitivity and reduce cardiovascular disease in high risk
type 2 diabetic patients, weight gain has been a limiting factor. Exenatide, another agent
used for treatment of T2DM, improves glycemic control and promotes moderate weight loss. In
this proposal we will examine the effect of combination therapy with pioglitazone plus
exenatide on body weight, fat topography, beta cell function, glycemic control, and plasma
lipid levels in subjects with type 2 diabetes mellitus compared to treatment with each drug
separately. Assessment of beta cell function will be performed by measuring the maximal
insulin secretory capacity using a maximal hyperglycemic stimulus combined with an
intravenous arginine stimulus.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio